GeoVax Labs (NASDAQ:GOVX) Shares Down 4.8%

GeoVax Labs, Inc. (NASDAQ:GOVX) shares were down 4.8% on Tuesday . The company traded as low as $1.50 and last traded at $1.60. Approximately 51,493 shares changed hands during mid-day trading, an increase of 35% from the average daily volume of 38,109 shares. The stock had previously closed at $1.68.

GeoVax Labs Trading Up 4.1 %

The stock has a fifty day simple moving average of $2.12 and a two-hundred day simple moving average of $4.80. The company has a market cap of $3.51 million, a PE ratio of -0.11 and a beta of 2.89.

Institutional Investors Weigh In On GeoVax Labs

Institutional investors have recently modified their holdings of the company. Millennium Management LLC purchased a new stake in shares of GeoVax Labs during the 2nd quarter worth approximately $27,000. Virtu Financial LLC purchased a new stake in shares of GeoVax Labs during the 1st quarter worth approximately $57,000. State Street Corp boosted its stake in shares of GeoVax Labs by 659.4% during the 3rd quarter. State Street Corp now owns 168,142 shares of the company’s stock worth $183,000 after acquiring an additional 146,000 shares in the last quarter. Geode Capital Management LLC boosted its stake in shares of GeoVax Labs by 18.1% during the 4th quarter. Geode Capital Management LLC now owns 172,750 shares of the company’s stock worth $108,000 after acquiring an additional 26,462 shares in the last quarter. Finally, Renaissance Technologies LLC purchased a new stake in shares of GeoVax Labs during the 2nd quarter worth approximately $333,000. Hedge funds and other institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.